• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个 Tat 突变体对 HIV-1 复制的强效抑制作用。

Potent inhibition of HIV-1 replication by a Tat mutant.

机构信息

Division of Infectious Diseases, Queensland Institute of Medical Research, Herston, Queensland, Australia.

出版信息

PLoS One. 2009 Nov 10;4(11):e7769. doi: 10.1371/journal.pone.0007769.

DOI:10.1371/journal.pone.0007769
PMID:19901984
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2768900/
Abstract

Herein we describe a mutant of the two-exon HIV-1 Tat protein, termed Nullbasic, that potently inhibits multiple steps of the HIV-1 replication cycle. Nullbasic was created by replacing the entire arginine-rich basic domain of wild type Tat with glycine/alanine residues. Like similarly mutated one-exon Tat mutants, Nullbasic exhibited transdominant negative effects on Tat-dependent transactivation. However, unlike previously reported mutants, we discovered that Nullbasic also strongly suppressed the expression of unspliced and singly-spliced viral mRNA, an activity likely caused by redistribution and thus functional inhibition of HIV-1 Rev. Furthermore, HIV-1 virion particles produced by cells expressing Nullbasic had severely reduced infectivity, a defect attributable to a reduced ability of the virions to undergo reverse transcription. Combination of these inhibitory effects on transactivation, Rev-dependent mRNA transport and reverse transcription meant that permissive cells constitutively expressing Nullbasic were highly resistant to a spreading infection by HIV-1. Nullbasic and its activities thus provide potential insights into the development of potent antiviral therapeutics that target multiple stages of HIV-1 infection.

摘要

在此,我们描述了一种 HIV-1 Tat 蛋白的突变体,称为 Nullbasic,它能有效地抑制 HIV-1 复制周期的多个步骤。Nullbasic 通过用甘氨酸/丙氨酸残基替换野生型 Tat 的整个富含精氨酸的碱性结构域而产生。与类似突变的单外显子 Tat 突变体一样,Nullbasic 对 Tat 依赖性反式激活表现出显性负效应。然而,与之前报道的突变体不同,我们发现 Nullbasic 还能强烈抑制未剪接和单剪接病毒 mRNA 的表达,这种活性可能是由于 HIV-1 Rev 的重新分布和因此功能抑制所致。此外,表达 Nullbasic 的细胞产生的 HIV-1 病毒粒子的感染力严重降低,这一缺陷归因于病毒粒子进行逆转录的能力降低。这些对反式激活、Rev 依赖的 mRNA 转运和逆转录的抑制作用的结合意味着,持续表达 Nullbasic 的许可细胞对 HIV-1 的传播感染具有高度抗性。Nullbasic 及其活性因此为开发针对 HIV-1 感染多个阶段的有效抗病毒治疗提供了潜在的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/dc2755a76379/pone.0007769.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/c85725098e0f/pone.0007769.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/b4e8c5d7987e/pone.0007769.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/51ce0f3a50e3/pone.0007769.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/da6521733956/pone.0007769.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/42cabef5369c/pone.0007769.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/bd4638dcb5f9/pone.0007769.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/1a84e9a19c9a/pone.0007769.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/dc2755a76379/pone.0007769.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/c85725098e0f/pone.0007769.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/b4e8c5d7987e/pone.0007769.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/51ce0f3a50e3/pone.0007769.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/da6521733956/pone.0007769.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/42cabef5369c/pone.0007769.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/bd4638dcb5f9/pone.0007769.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/1a84e9a19c9a/pone.0007769.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0fb/2768900/dc2755a76379/pone.0007769.g008.jpg

相似文献

1
Potent inhibition of HIV-1 replication by a Tat mutant.一个 Tat 突变体对 HIV-1 复制的强效抑制作用。
PLoS One. 2009 Nov 10;4(11):e7769. doi: 10.1371/journal.pone.0007769.
2
A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1.一种HIV-1反式激活因子(Tat)突变蛋白通过靶向DEAD盒RNA解旋酶DDX1破坏HIV-1调节蛋白(Rev)的功能。
Retrovirology. 2014 Dec 14;11:121. doi: 10.1186/s12977-014-0121-9.
3
A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.突变的 Tat 蛋白可为人源 CD4+T 细胞提供针对 HIV-1 感染的强大保护。
Hum Gene Ther. 2013 Mar;24(3):270-82. doi: 10.1089/hum.2012.176. Epub 2013 Mar 1.
4
A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes.一种突变的反式激活转录蛋白(Tat蛋白)可抑制来自不同HIV-1亚型的毒株对人类细胞的感染。
Virol J. 2017 Mar 14;14(1):52. doi: 10.1186/s12985-017-0705-9.
5
A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.一种突变的反式激活蛋白通过靶向逆转录复合物来抑制HIV-1逆转录。
J Virol. 2015 May;89(9):4827-36. doi: 10.1128/JVI.03440-14. Epub 2015 Feb 11.
6
Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein.Nullbasic(一种突变的Tat蛋白)对T细胞中HIV-1转录的抑制作用。
mBio. 2016 Jul 5;7(4):e00518-16. doi: 10.1128/mBio.00518-16.
7
Strong Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant.Nullbasic,一种 Tat 突变体,可强烈抑制 HIV-1 的复制。
mBio. 2019 Aug 27;10(4):e01769-19. doi: 10.1128/mBio.01769-19.
8
Differential Effects of Strategies to Improve the Transduction Efficiency of Lentiviral Vector that Conveys an Anti-HIV Protein, Nullbasic, in Human T Cells.提高携带抗 HIV 蛋白 Nullbasic 的慢病毒载体转导效率的策略的差异效应。在人 T 细胞中。
Virol Sin. 2018 Apr;33(2):142-152. doi: 10.1007/s12250-018-0004-7. Epub 2018 Mar 14.
9
Construction and characterization of a potent HIV-2 Tat transdominant mutant protein.一种高效HIV-2反式显性突变蛋白的构建与表征
J Acquir Immune Defic Syndr (1988). 1994 Jul;7(7):655-64.
10
Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins.利用Tat突变体和阻遏域融合蛋白抑制Tat介导的反式激活和HIV复制。
Gene Ther. 1998 Jul;5(7):946-54. doi: 10.1038/sj.gt.3300676.

引用本文的文献

1
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?对艾滋病治愈病例的深度思考:我们走过了哪些历程,未来又将如何?
Biomolecules. 2025 Mar 5;15(3):378. doi: 10.3390/biom15030378.
2
Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV.利用抗病毒RNA干扰疗法治疗大流行病毒:严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和人类免疫缺陷病毒(HIV)
Drug Deliv Transl Res. 2025 Jan 20. doi: 10.1007/s13346-025-01788-x.
3
Enhanced NF-κB activation via HIV-1 Tat-TRAF6 cross-talk.通过 HIV-1 Tat-TRAF6 相互作用增强 NF-κB 激活。

本文引用的文献

1
Nucleocapsid mutations turn HIV-1 into a DNA-containing virus.核衣壳突变使HIV-1变成一种含DNA的病毒。
Nucleic Acids Res. 2008 Apr;36(7):2311-9. doi: 10.1093/nar/gkn069. Epub 2008 Feb 22.
2
Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro.细胞因子在体外刺激1型人类免疫缺陷病毒逆转录。
J Virol. 2008 Feb;82(3):1425-37. doi: 10.1128/JVI.01808-07. Epub 2007 Nov 28.
3
The HIV-1 Tat protein stimulates reverse transcription in vitro.HIV-1反式激活蛋白在体外可刺激逆转录。
Sci Adv. 2024 Jan 19;10(3):eadi4162. doi: 10.1126/sciadv.adi4162.
4
Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.打破沉默:治愈艾滋病道路上的 HIV 转录和潜伏期调控。
Viruses. 2023 Dec 15;15(12):2435. doi: 10.3390/v15122435.
5
Sulforaphane prevents the reactivation of HIV-1 by suppressing NFκB signaling.萝卜硫素通过抑制核因子κB信号通路来防止HIV-1重新激活。
J Virus Erad. 2023 Aug 12;9(3):100341. doi: 10.1016/j.jve.2023.100341. eCollection 2023 Sep.
6
GigaAssay - An adaptable high-throughput saturation mutagenesis assay platform.GigaAssay-一种适应性强的高通量饱和突变检测平台。
Genomics. 2022 Jul;114(4):110439. doi: 10.1016/j.ygeno.2022.110439. Epub 2022 Jul 26.
7
Synaptic dysfunction is associated with alterations in the initiation of goal-directed behaviors: Implications for HIV-1-associated apathy.突触功能障碍与目标导向行为的启动改变有关:对 HIV-1 相关淡漠的影响。
Exp Neurol. 2022 Nov;357:114174. doi: 10.1016/j.expneurol.2022.114174. Epub 2022 Jul 18.
8
So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.如此致病还是怎样?——重点介绍 SIV 发病机制的简要概述及治愈研究
Viruses. 2022 Jan 12;14(1):135. doi: 10.3390/v14010135.
9
Cure and Long-Term Remission Strategies.治愈与长期缓解策略
Methods Mol Biol. 2022;2407:391-428. doi: 10.1007/978-1-0716-1871-4_26.
10
Induction of Autophagy to Achieve a Human Immunodeficiency Virus Type 1 Cure.诱导自噬以实现人类免疫缺陷病毒 1 型的治愈。
Cells. 2021 Jul 16;10(7):1798. doi: 10.3390/cells10071798.
Curr HIV Res. 2007 Sep;5(5):473-83. doi: 10.2174/157016207781662443.
4
Posttranscriptional control of HIV-1 and other retroviruses and its practical applications.人类免疫缺陷病毒1型及其他逆转录病毒的转录后调控及其实际应用
Adv Pharmacol. 2007;55:161-97. doi: 10.1016/S1054-3589(07)55005-2.
5
In vivo study of HIV-1 Tat arginine-rich motif unveils its transport properties.人类免疫缺陷病毒1型反式激活因子富含精氨酸基序的体内研究揭示了其转运特性。
Mol Ther. 2007 Jul;15(7):1313-22. doi: 10.1038/sj.mt.6300172. Epub 2007 May 1.
6
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.对从感染的单核细胞衍生巨噬细胞中产生的纯化1型人类免疫缺陷病毒进行蛋白质组学和生化分析。
J Virol. 2006 Sep;80(18):9039-52. doi: 10.1128/JVI.01013-06.
7
RTE and CTE mRNA export elements synergistically increase expression of unstable, Rev-dependent HIV and SIV mRNAs.RTE和CTE mRNA输出元件协同增加不稳定的、依赖Rev的HIV和SIV mRNA的表达。
Retrovirology. 2006 Jan 13;3:6. doi: 10.1186/1742-4690-3-6.
8
Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication.1型人类免疫缺陷病毒蛋白酶对tat活性的调节对于高效逆转录和复制至关重要。
J Virol. 2003 Sep;77(18):9912-21. doi: 10.1128/jvi.77.18.9912-9921.2003.
9
Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes.通过慢病毒载体介导特定基因转移实现人原代细胞的可逆永生化
Mol Ther. 2000 Oct;2(4):404-14. doi: 10.1006/mthe.2000.0141.
10
Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates.1型人类免疫缺陷病毒组装的动力学分析揭示了连续中间体的存在。
J Virol. 2000 Jul;74(13):5845-55. doi: 10.1128/jvi.74.13.5845-5855.2000.